206 articles with NovoCure Ltd.
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China
Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan
Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer
US Oncology Research will open 10 clinical trial sites, enrolling patients in Novocure’s PANOVA-3 trial to test the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer
Novocure announced that it will participate in two upcoming investor conferences.
Jeryl Hilleman, Chief Financial Officer of Intersect ENT, elected to board of directors
Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer
Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls.
Quarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the first quarter 2018
The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference
Scientific Track Dedicated to Tumor Treating Fields at 40th International Conference of the IEEE Engineering in Medicine and Biology Society
The IEEE Engineering in Medicine and Biology Society’s 40th International Conference is the first conference in which a scientific track will be devoted to Tumor Treating Fields, increasing the awareness of Novocure’s proprietary cancer therapy among the scientific community
With extensive experience in oncology, Pritesh Shah will be responsible for Novocure’s commercial strategy worldwide
Novocure announced today that it will report financial results for the second quarter 2018 on Thursday, July 26, 2018, before the U.S. financial markets open.
Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer
Novocure announced changes to its board of directors. Dr. David T. Hung and Sherilyn D. McCoy, both experienced executive leaders, were elected to Novocure’s board at the annual general meeting of shareholders on May 31.
2,009 active patients at March 31, 2018, an increase of 59 percent versus March 31, 2017
Final STELLAR data exceeded the results of the interim analysis for all efficacy endpoints
NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma
Updated clinical practice guidelines indicate, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate
Delivered record quarterly net revenues of $53.7 million, representing 77 percent growth versus December 31, 2016, and 7 percent growth versus September 30, 2017
The cash will be used to to execute core strategies of driving commercial adoption of Optune and advancing the clinical pipeline.
Novocure plans to discuss these results with investors at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco.
Novocure Release: JAMA Publishes Final Analysis of EF-14 Phase III Pivotal Trial of Optune Together With Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma
Novacure announced today that the final analysis of its phase 3 pivotal trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM) has been published in the Journal of the American Medical Association (JAMA).
Novocure Receives FDA IDE Approval for Its PANOVA 3 Phase III Pivotal Clinical Trial in Advanced ...
12/18/2017NovoCure announced today that it has received a FDA Investigational Device Exemption (IDE) approval to initiate its PANOVA 3 clinical trial.